<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00319670</url>
  </required_header>
  <id_info>
    <org_study_id>851-201</org_study_id>
    <nct_id>NCT00319670</nct_id>
  </id_info>
  <brief_title>A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children</brief_title>
  <official_title>A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <brief_summary>
    <textblock>
      To evaluate patient acceptance of a new MiraLax dose formulation in children currently
      treated with polyethylene glycol 3350 powder for treatment of constipation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate patient acceptance of a new MiraLax dose formulation in children currently
      treated with polyethylene glycol 3350 powder for treatment of constipation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy will be measured by analysis of patient self-reported BM data.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events will be monitored and analyzed for safety purposes.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient acceptance will be measured by analysis of subjective questionnaire data.</measure>
  </secondary_outcome>
  <enrollment>25</enrollment>
  <condition>Constipation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MiraLax</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female constipated outpatients between the ages of 4 and 16

          2. Currently taking a dose of less than or equal to 17g of PEG 3350 powder that has been
             consistent for at least 4 weeks

          3. Current treatment is considered successful - defined as greater than 2 bowel movements
             per week with no accidents

          4. Are otherwise in good health, as judged by a physical examination

          5. If female and of childbearing potential, patient must be using oral contraceptives,
             depot contraceptives, intrauterine device, or testifies that she is monogamous with a
             vasectomized partner, or practices abstinence and will continue to do so during the
             duration of study

          6. In the investigator's judgment, patient or guardian is mentally competent to sign an
             instrument of informed consent

        Exclusion Criteria:

          1. Patients with heme positive stool at baseline exam

          2. Patients who are impacted at baseline exam

          3. Patients that are not receiving PEG 3350

          4. Patients on PEG 3350 that continue to have problems

          5. Patients with known or suspected perforation or obstruction

          6. Patients with a history of gastric retention, inflammatory bowel disease, bowel
             resection, or colostomy

          7. Patients with a known history of organic cause for their constipation.

          8. Patients currently using medications known to cause constipation. These include
             Opiates, antidepressants, SSRI's, antimotility agents and anticholinergics.

          9. Patients who are breastfeeding, pregnant, or intend to become pregnant during the
             study

         10. Female patients of childbearing potential who refuse a pregnancy test

         11. Patients who, in the opinion of the investigator, should not be included in the study
             for any reason, including inability to follow study procedure

         12. Patients with known allergy to PEG or PEG containing medications

         13. Patients who, within the past 30 days have participated in an investigational clinical
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Nurko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2006</study_first_submitted>
  <study_first_submitted_qc>April 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <keyword>constipation</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyethylene glycol 3350</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

